portola pharmaceuticals stock price

The stock price has decreased by -31.91% in the last 52 weeks. Rare disease drugmaker Alexion will buy Portola Pharmaceuticals for $1.44 billion, the latest deal aimed at expanding its business beyond Soliris, its flagship product and top-selling therapy. PTLA Stocks Year by Year Growth; Growth of 1000$ On PTLA Stock Vs S&P 500 Growth; Growth of 1000$ On PTLA Vs Gold ; 1 What would $1000 invested in Portola Pharmaceuticals Inc (PTLA) shares be worth now? Free trial. Price trends tend to persist, so it's worth looking at them when it comes to a share like Portola Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -33.23%. SOUTH SAN FRANCISCO, Calif., Aug. 13, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the pricing of its underwritten public offering of 8,035,715 shares of its common stock at a price to the public of $28.00 per share. Market capitalization of Portola Pharmaceuticals (PTLA) Market cap: $1.41 B As of March 2021 Portola Pharmaceuticals has a market cap of $1.41 B.This makes Portola Pharmaceuticals the world's 3470th most valuable company by market cap according to our data. for only . using the scroll bar or pinch and zoom on a touch screen). K ey Conclusion The outlook for Portola’s stock price in 2019 and 2020 will almost certainly driven by the sales progress of Andexxa. On January 9, 2020, Portola Pharmaceuticals announced that its preliminary unaudited Andexxa global net revenues came in far below estimates. Portola Pharmaceuticals Inc (NASDAQ: ... and the $15.17 average price target suggests a 124% upside from the current $6.76 trading price. VAT not included. Implied Volatility Surging for Portola Pharmaceuticals (PTLA) Stock … At this early stage in the launch, there is considerable uncertainty and guesswork involved in projecting sales. Portola Pharmaceuticals (NASDAQ:PTLA) slumps 39% after hours in reaction to preliminary Q4 and 2019 results that are significantly below consensus. It opened the trading session at $17.94, the shares rose to $17.96 and dropped to $17.92, the range by which the price of stock traded the whole day. Visit PTLA's SEC page to see the company's official filings. Free trial. 36.49. Free trial. $34.10. The last trading period has seen Portola Pharmaceuticals Inc. (PTLA) move -44.06% and 234.27% from the stock’s 52-week high and 52-week low prices respectively. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer... | December 23, 2020 In the short term (2weeks), PTLA's stock price should underperform the market by -0.45%.During that period the price should oscillate between … 645,483 +0.89 (2.50%) Updated May 3, 2019 04:00 PM ET. Portola Stock News: Stock drops over 40% on Andexxa Revenue Announcement . The daily trading volume for Portola Pharmaceuticals Inc. (NASDAQ:PTLA) over the last session is 4.69 million shares. To help provide a sense of the short to long-term trend, included is an interactive Portola Pharmaceuticals stock chart which you can easily adjust to the time frame of your choosing (e.g. Over the last 12 months, PTLA stock dropped by -31.71%. Stocks with similar financial metrics, market capitalization, and price volatility to Portola Pharmaceuticals Inc are KALA, NSTG, DVAX, ORGS, and BGMD. Last 30 Days. Portola is now a wholly owned subsidiary of Alexion. Portola Pharmaceuticals, Inc. (PTLA) (Delayed Data from NSDQ) $36.49 USD. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) shareholders will doubtless be very grateful to see the share price up 152% in the last month.But over the last three years we’ve seen a quite serious decline. 2. Portola reported 2019 sales of $111.5 million for Andexxa, which is marketed as Ondexxya in Europe. An important predictor of whether a stock price will go up is its track record of momentum. 11 )* Portola Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 737010108 … Portola Pharmaceuticals Stock Price . Today, Portola Pharmaceuticals is trading at $19.32, which is a ~7.52% decline from yesterday’s close of $20.89 on December 10. The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." Alexion will pay $18 per share for Portola, a roughly 130% premium over Portola's closing stock price on May 4. Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. In terms of volatility of its share price, PTLA is more volatile than 90.67% of stocks we're observing. Portola Pharmaceuticals Inc. [NASDAQ: PTLA] stock went on an upward path that rose over 0.17% on Wednesday, amounting to a one-week price increase of more than 0.06%. Portola Pharmaceuticals Stock Forecast NASDAQ:PTLA Price Target and Analyst Ratings. Monthly Subscription. 18.03 0.00 (0.0%) Upgrade to Real-Time Afterhours (Closed) Best deals to access real time data! Follow PTLA. Morgan Stanley does not see either upside or downside right now giving PTLA "Equal Weight" on their last update on May 08, 2020. Most Recent Rating . Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Note: We will be using adjusted close prices for calculations. Price is a widely used stock evaluation measure. PTLA Price (Portola Pharmaceuticals stock price per share) $18.03 × PE Ratio Versus Sector. Indeed, the share price is down a tragic 57% in the last three years. The beta is 2.31, so PTLA's price volatility has been higher than the market average. After-Market: $36.46 (%) 5:22 PM ET. The first section will let you know the impact on $1000 in Portola Pharmaceuticals Inc (PTLA) due to the share price changes. (See Orchard’s stock analysis at TipRanks.) DDE w/Realtime (Monthly) Monthly Subscription. $49.05. 06-09 sec.gov - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. Stock Price Statistics. Big Cap Pro. Portola Pharmaceuticals, Inc. Stock Price Forecast, "PTLA" Predictons for2021 AstraZeneca has a portfolio of products for major diseases including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation areas.. Portola Pharmaceuticals Inc. [NASDAQ: PTLA] loss 0.00% or 0.0 points to close at $17.94 with a heavy trading volume of 1150207 shares. Read more. A high-level overview of Portola Pharmaceuticals, Inc. (PTLA) stock. $52.04. In addition, the underwriters of the offering have been granted a 30-day option to purchase up to an additional 1,205,357 shares from Portola … (RTTNews) - Alexion Pharmaceuticals, Inc. (ALXN) and Portola Pharmaceuticals, Inc. (PTLA) have entered into a definitive merger agreement for Alexion to acquire Portola… PTLA has attracted considerable attention from traders and investors, a scenario that has seen its volume jump … The PE ratio measures the reported earnings of a company to its current stock price. The one-year Portola Pharmaceuticals Inc. stock forecast points to a potential upside of 7.67. PTLA stock forecast Our latest prediction for Portola Pharmaceuticals, Inc.'s stock price was made on the April 4, 2019 when the stock price was at 37.41$.. Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. Use our historic performance chart to see real-time Portola Pharmaceuticals Inc stock price and the Portola Pharmaceuticals Inc news feed to help further your research before investing in fractional shares with any dollar amount you choose. The tender offer for all of the outstanding shares of common stock of Portola at a price of $18.00 per share expired as scheduled, one minute following 11:59 p.m., New York City time, on July 1, 2020. AstraZeneca plc (/ ˌ æ s t r ə ˈ z ɛ n ə k ə /) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters in Cambridge, England. PTLA / Portola Pharmaceuticals, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment. Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. According to the announcement, the company estimates Andexxa revenues to be around $28 million for the fourth quarter. The price target was set to $14.00 → $18.00. for only. Q4 Andexxa/Ondexxya sales will be ~$32M. Small Cap Pro. The following presents a detailed Portola Pharmaceuticals stock price history for your review. Add to portfolio. Monthly Subscription. Under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola’s common stock at a price of $18 per share in cash. Choose a Stash plan and set up your investment account in just a few minutes. While earnings are easy to manipulate on the balance sheet, this ratio gives you a sense of what buyers are willing to pay for the stock—what they believe it will do in the future. Alexion is paying a healthy premium over Portola’s closing price on Tuesday. Historical Ratings. for only. The average equity rating for PTLA stock is currently 2.70, trading …

Cold Shipping Boxes, Nimesil Berlin-chemie Menarini, Formel 1 Fanshop Deutschland, Xylocain Spray 10, Schweinefleisch Konsum Deutschland, Erklärung Definition Jura, Annette Schavan Mann, Stockmeyer Gmbh Tierhaltung, Daniel Günther Live Heute, Von Ganzem Herzen Danken Englisch, Navid F Influencer,